These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 20370378)

  • 1. A 26-week, placebo- and pioglitazone-controlled, dose-ranging study of rivoglitazone, a novel thiazolidinedione for the treatment of type 2 diabetes.
    Truitt KE; Goldberg RB; Rosenstock J; Chou HS; Merante D; Triscari J; Wang AC
    Curr Med Res Opin; 2010 Jun; 26(6):1321-31. PubMed ID: 20370378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 26-week, placebo- and pioglitazone-controlled monotherapy study of rivoglitazone in subjects with type 2 diabetes mellitus.
    Chou HS; Truitt KE; Moberly JB; Merante D; Choi Y; Mun Y; Pfützner A
    Diabetes Obes Metab; 2012 Nov; 14(11):1000-9. PubMed ID: 22686944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes.
    Kong AP; Yamasaki A; Ozaki R; Saito H; Asami T; Ohwada S; Ko GT; Wong CK; Leung GT; Lee KF; Yeung CY; Chan JC
    Diabetes Obes Metab; 2011 Sep; 13(9):806-13. PubMed ID: 21492364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
    Pratley RE; Reusch JE; Fleck PR; Wilson CA; Mekki Q;
    Curr Med Res Opin; 2009 Oct; 25(10):2361-71. PubMed ID: 19650752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years.
    Norwood P; Liutkus JF; Haber H; Pintilei E; Boardman MK; Trautmann ME
    Clin Ther; 2012 Oct; 34(10):2082-90. PubMed ID: 23031623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus.
    Herz M; Johns D; Reviriego J; Grossman LD; Godin C; Duran S; Hawkins F; Lochnan H; Escobar-Jiménez F; Hardin PA; Konkoy CS; Tan MH
    Clin Ther; 2003 Apr; 25(4):1074-95. PubMed ID: 12809958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
    Bergenstal RM; Wysham C; Macconell L; Malloy J; Walsh B; Yan P; Wilhelm K; Malone J; Porter LE;
    Lancet; 2010 Aug; 376(9739):431-9. PubMed ID: 20580422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy.
    Rosenstock J; Vico M; Wei L; Salsali A; List JF
    Diabetes Care; 2012 Jul; 35(7):1473-8. PubMed ID: 22446170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of therapy with metformin plus pioglitazone in the treatment of patients with type 2 diabetes: a double-blind, placebo-controlled, clinical trial.
    Kaku K
    Curr Med Res Opin; 2009 May; 25(5):1111-9. PubMed ID: 19309251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
    Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide.
    Wysham C; Bergenstal R; Malloy J; Yan P; Walsh B; Malone J; Taylor K
    Diabet Med; 2011 Jun; 28(6):705-14. PubMed ID: 21434995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Roberts VL; Stewart J; Issa M; Lake B; Melis R
    Clin Ther; 2005 Oct; 27(10):1535-47. PubMed ID: 16330290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy.
    Henriksen K; Byrjalsen I; Qvist P; Beck-Nielsen H; Hansen G; Riis BJ; Perrild H; Svendsen OL; Gram J; Karsdal MA; Christiansen C;
    Diabetes Metab Res Rev; 2011 May; 27(4):392-401. PubMed ID: 21328517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study.
    Henry RR; Lincoff AM; Mudaliar S; Rabbia M; Chognot C; Herz M
    Lancet; 2009 Jul; 374(9684):126-35. PubMed ID: 19515415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rivoglitazone: a new thiazolidinedione for the treatment of type 2 diabetes mellitus.
    Koffarnus RL; Wargo KA; Phillippe HM
    Ann Pharmacother; 2013 Jun; 47(6):877-85. PubMed ID: 23632280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study.
    Gomis R; Espadero RM; Jones R; Woerle HJ; Dugi KA
    Diabetes Obes Metab; 2011 Jul; 13(7):653-61. PubMed ID: 21410628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone.
    Hollander P; Li J; Allen E; Chen R;
    J Clin Endocrinol Metab; 2009 Dec; 94(12):4810-9. PubMed ID: 19864452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pioglitazone is effective therapy for elderly patients with type 2 diabetes mellitus.
    Rajagopalan R; Perez A; Ye Z; Khan M; Murray FT
    Drugs Aging; 2004; 21(4):259-71. PubMed ID: 15012171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of rosiglitazone and pioglitazone in drug-naïve Japanese patients with type 2 diabetes mellitus: a double-blind, 28 weeks' treatment, comparative study.
    Kikuchi M; Kaku K; Odawara M; Momomura S; Ishii R
    Curr Med Res Opin; 2012 Jun; 28(6):1007-16. PubMed ID: 22587483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin.
    Liutkus J; Rosas Guzman J; Norwood P; Pop L; Northrup J; Cao D; Trautmann M
    Diabetes Obes Metab; 2010 Dec; 12(12):1058-65. PubMed ID: 20977576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.